Citations

Showing 10 of 108104 citations.

Faculty Opinions recommendation of Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States.
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727114840.793553311 Get It

Faculty Opinions recommendation of Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study.
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725410449.793553314 Get It

Faculty Opinions recommendation of Complete neoadjuvant treatment for rectal cancer: the brown university oncology group CONTRE study.
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725227701.793553313 Get It

Faculty Opinions recommendation of Robotics in urology.
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734475810.793553307 Get It

Faculty Opinions recommendation of St.Gallen consensus on safe implementation of transanal total mesorectal excision.
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732292726.793553305 Get It

Faculty Opinions recommendation of An assessment of an Australasian pathway for the introduction of transanal total mesorectal excision (taTME).
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732147071.793553306 Get It

Faculty Opinions recommendation of Robotic-Assisted Surgery Improves the Quality of Total Mesorectal Excision for Rectal Cancer Compared to Laparoscopy: Results of a Case-Controlled Analysis.
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725952842.793553308 Get It

Faculty Opinions recommendation of Laparoscopic versus robotic-assisted colectomy and rectal resection: a systematic review and meta-analysis.
Mathis, Kellie L.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.730964029.793553304 Get It

A Review on Electroporation-Based Intracellular Delivery
Shi, Junfeng, Ma, Yifan , Zhu, Jing , Chen, Yuanxin , Sun, Yating , Yao, Yicheng, Yang, Zhaogang , Xie, Jing

Mayo Clinic

Molecules | November 22, 2018 | Volume: 23 | Issue: 11 | Pages: 3044

10.3390/molecules23113044 | PMID 30469344 Get It

Intracellular delivery is a critical step in biological discoveries and has been widely utilized in biomedical research. A variety of molecular tools have been developed for cell-based gene therapies, including FDA approved CAR-T immunotherapy, iPSC, cell reprogramming and gene editing. Despite the inspiring results of these applications, intracellular delivery of foreign molecules including nucleic acids and proteins remains challenging. Efficient yet non-invasive delivery of biomolecules in a high-throughput manner has thus long fascinates the scientific community. As one of the most popular non-viral technologies for cell transfection, electroporation has gone through enormous development with the assist of nanotechnology and microfabrication. Emergence of miniatured electroporation system brought up many merits over the weakness of traditional electroporation system, including precise dose control and high cell viability. These new generation of electroporation systems are of considerable importance to expand the biological applications of intracellular delivery, bypassing the potential safety issue of viral vectors. In this review, we will go over the recent progresses in the electroporation-based intracellular delivery and several potential applications of cutting-edge research on the miniatured electroporation, including gene therapy, cellular reprogramming and intracellular probe.
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Sterner, Rosalie M. , Cox, Michelle J. , Yang, Nan , Khadka, Roman H., Forsman, Cynthia L. , Hansen, Michael J. , Ayasoufi, Katayoun , Schick, Kendall J. , Walters, Denise K., Ahmed, Omar, Chappell, Dale, Sahmoud, Tarek, Durrant, Cameron, Nevala, Wendy K. , Patnaik, Mrinal M. , Pease, Larry R. , Hedin, Karen E. , Johnson, Aaron J. , Cox, Michelle J , Ayasoufi, Katayoun , Sakemura, Reona , Jin, Fang , Hefazi, Mehrdad , Ahmed, Omar, Kay, Neil E. , Johnson, Aaron J. , Kenderian, Saad S.

Mayo Clinic

Blood | November 22, 2018 | Volume: 133 | Issue: 7 | Pages: 697-709

10.1182/blood-2018-10-881722 | PMID 30463995 Get It

Abstract Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited by the associated toxicities. These include cytokine release syndrome (CRS) and neurotoxicity. Although the IL-6R antagonist tocilizumab is approved for treatment of CRS, there is no approved treatment of neurotoxicity associated with CD19-targeted CAR-T (CART19) cell therapy. Recent data suggest that monocytes and macrophages contribute to the development of CRS and neurotoxicity after CAR-T cell therapy. Therefore, we investigated neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) as a potential strategy to manage CART19 cell–associated toxicities. In this study, we show that GM-CSF neutralization with lenzilumab does not inhibit CART19 cell function in vitro or in vivo. Moreover, CART19 cell proliferation was enhanced and durable control of leukemic disease was maintained better in patient-derived xenografts after GM-CSF neutralization with lenzilumab. In a patient acute lymphoblastic leukemia xenograft model of CRS and neuroinflammation (NI), GM-CSF neutralization resulted in a reduction of myeloid and T cell infiltration in the central nervous system and a significant reduction in NI and prevention of CRS. Finally, we generated GM-CSF–deficient CART19 cells through CRISPR/Cas9 disruption of GM-CSF during CAR-T cell manufacturing. These GM-CSFk/o CAR-T cells maintained normal functions and had enhanced antitumor activity in vivo, as well as improved overall survival, compared with CART19 cells. Together, these studies illuminate a novel approach to abrogate NI and CRS through GM-CSF neutralization, which may potentially enhance CAR-T cell function. Phase 2 studies with lenzilumab in combination with CART19 cell therapy are planned.